ly
Lv1
40 积分
2023-11-22 加入
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
6天前
已完结
-
Maintenance therapy in patients with mycosis fungoides or Sézary syndrome: A neglected topic
11天前
已完结
-
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1个月前
已完结
-
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
1个月前
已完结
-
Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate
2个月前
已完结
-
Aromatase inhibitors: Role in postmenopausal breast cancer
2个月前
已完结
-
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
2个月前
已完结
-
Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy
2个月前
已关闭
-
Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia
2个月前
已完结
-
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia
3个月前
已完结